Among the drugs used for acute ischemic stroke, recombinant tissue plasminogen activator is widely accepted in the world of medicine. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke. Pro-urokinase is the precursor of urokinase. Compared with urokinase, pro-urokinase has greater ability to dissolve thrombus and is safer to use. However, most countries do not recognize urokinase for thrombolytic treatment after acute ischemic stroke, which has not been approved for clinical use.
Dr. Wenli Hu and team from Beijing Chao-Yang Hospital, Capital Medical University in China compared the thrombolytic effects of pro-urokinase, recombinant tissue plasminogen activator, and urokinase in a dog model of acute cerebral embolism. They found that jematoxylin and eosin staining showed no hematoma in the infarcted area after thrombolysis with any of the three therapies, and neuronal apoptosis after cerebral infarction was also not attenuated. The results of angiography showed that recanalization after thromboembolism was similar after thrombolysis with pro-urokinase and recombinant tissue plasminogen activator, and that both these drugs were more effective than urokinase. The relevant article was published in the Neural Regeneration Research
(Vol. 9, No. 5, 2014).
Show Full Article